Inhalation Anesthesia: Global Market Size Share & Trends Analysis Report 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Inhalation
Anesthesia Market Size Share & Trends Analysis Report By Application
(Induction, Maintenance), By Product (Sevoflurane, Isoflurane,
Desflurane), By Region, And Segment Forecasts, 2019 – 2025”
report has been added to ResearchAndMarkets.com’s
offering.

The global inhalation anesthesia market size is projected to reach USD
1.42 billion by 2015, at a lucrative CAGR of 3.5% over the forecast
period, according to this new report. Key factors contributing to its
rapid growth include increasing prevalence of cancer, cardiovascular,
respiratory, neurological, gastrointestinal, orthopedic, and spinal
diseases and disorders.

Furthermore, increasing number of emergency cases and demand for short
stay ambulatory day care surgical procedure are amongst critical success
factors attributed to the market growth. Access to universal health
insurance coverage for a wider population base coupled with constant
improvements in healthcare infrastructure in various developing
countries are expected to positively impact the number of surgeries
performed, thus increasing the usage of inhalation anesthetics.

On the basis of product, the inhalation anesthesia market is classified
into sevoflurane, isoflurane, and desflurane. These products are used
for induction and maintenance of anesthesia for patients during surgical
procedures. Sevoflurane led the product segment in 2018 and is
anticipated to grow at a lucrative rate over the forecast period,
attributed to its therapeutic advantages, low cost, and higher potency
for the induction of anesthesia. On the other hand, isoflurane is
expected to witness the fastest CAGR of 6.3% over the forecast period,
due to its increasing use in maintenance of anesthesia for treatment of
weak or geriatric patients owing to its sparing effect on cardiovascular
function.

On the basis of regions, the market is broadly classified into North
America, Europe, Asia Pacific, Latin America, and Middle East and Africa
(MEA). North America held the leading market share of USD 456.0 million
and is anticipated to witness lucrative CAGR over the forecast period.
This is owing to increasing prevalence of chronic diseases coupled with
the presence of advanced healthcare facilities. On the other hand, Asia
Pacific was anticipated to witness the fastest CAGR of 4.0% due to
increasing population and number of patients suffering from chronic
population.

Some of the key players operating in this market include Halocarbon
Products Corporation; Baxter; Hikima Pharmaceuticals PLC; Lunan
Pharmaceutical Group Co. Ltd.; Piramal Enterprises Limited; Jiangsu
Hengrui Medicine Co. Ltd.; Fresenius Kabi AG, and AbbVie Inc.

Further key findings from the report suggest:

• Sevoflurane product segment led the market in terms of revenue, valued
  at USD 768.6 million, in 2018
• Isoflurane product segment is anticipated to expand at the fastest
  CAGR of 6.3% owing to its increasing use in the treatment of weak and
  geriatric patients owing to its low effect on cardiovascular function
• North America led the market in 2018 with a revenue of USD 456 million
  owing to the presence of advanced healthcare facilities, strong
  reimbursement scenario, and prevalence of chronic diseases

Key Companies Mentioned

• Halocarbon Products Corporation
• Baxter
• Hikima Pharmaceuticals plc
• Luman Pharmaceutical Group Co. Ltd.
• Piramal Enterprises Limited
• Jiangsu Hengrui Medicine Co. Ltd.
• Fresenius Kabi AG
• AbbVie Inc.

For more information about this report visit https://www.researchandmarkets.com/r/ovvbbh

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Anesthetic
Drugs